Sage Journals: Discover world-class research

Abstract

A series of 4-anilinoquinazoline–triazole–AZT hybrids were designed and synthesized as anticancer agents. Their cytotoxic potential has been evaluated by means of a micro-dilution assay against three human cancer cell lines (KB, epidermoid carcinoma; HepG2, hepatoma carcinoma; SK-Lu-1, non-small lung cancer). The biological results revealed that compounds 4b and 6d showed good anticancer activities against KB, HepG2, and Lu cell lines (IC₅₀ values ranging from 9 μM to 100 μM). Especially, compounds 4b and 6d exhibited up to 3-fold more potent than reference drugs erlotinib hydrochloride and AZT in term of anti-lung cancer activity.

Keywords

4-Anilinoquinazoline Triazole AZT Hybrids Anticancer agents

References

Thatipamula

R.K.

, Narsimha

, Battula

K.V.

, Rajendra Chary

, Mamidala

, Reddy

N.V.

(2007) Synthesis, anticancer and antibacterial evaluation of novel (isopropylidene)uridine-[1,2,3]triazole hybrids. Journal of Saudi Chemical Society, 21, 795–802.

Alaoui

, Dufies

, Driowya

, Demange

, Bougrin

, Robert

, Auberger

, Pagès

, Benhida

(2017) Synthesis and anti-cancer activities of new sulfonamides 4-substituted-triazolyl nucleosides. Bioorganic & Medicinal Chemistry Letters, 27, 1989–1992.

Andreuccetti

, Allegrini

, Antonuzzo

, Malvaldi

, Conte

P.F.

, Danesi

, Del Tacca

, Falcone

(1996) Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: In vitro synergistic cytotoxicity and DNA-induced strand-breaks. European Journal of Cancer, 32A, 1219–1226.

Johnston

J.S.

, Johnson

, Gan

, Wientjes

M.G.

, Au

J.L.

(2003) Synergy between 3'-azido-3'-deoxythymidine and paclitaxel in human pharynx FaDu cells. Pharmaceutical Research, 20, 957–961.

Mattson

D.M.

, Ahmad

I.M.

, Dayal

, Parsons

A.D.

, Aykin-Burns

, Li

, Orcutt

K.P.

, Spitz

D.R.

, Dornfeld

K.J.

, Simons

A.L.

(2009) Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism. Free Radical Biology & Medicine, 46, 232–237.

Stamos

, Sliwkowski

M.X.

, Eigenbrot

(2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. Journal of Biological Chemistry, 277, 46265–46272.

Ghorab

M.M.

, Alsaid

M.S.

(2015) Novel 4-aminoquinazoline derivatives as new leads for anticancer drug discovery. Acta Pharmaceutica, 65, 299–309.

Montagu

, Roy

, Balzarini

, Snoeck

, Andrei

, Agrofoglio

L.A.

(2011) Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation. European Journal of Medicinal Chemistry, 46, 778–786.

J.L.

, Wu

Q.P.

, Zhang

Q.S.

, Liu

Y.H.

, Li

Y.Z.

, Zhou

Z.M.

(2010) Synthesis and antitumor activity of novel 2’,3'-dideoxy-2’,3'-diethanethionucleosides bearing 1,2,3-triazole residues. Bioorganic Medicinal Chemistry Letters, 20, 240–243.

10.

Amblard

, Cho

J.H.

, Schinazi

R.F.

(2009) Cu(I)-Catalyzed Huisgen azide-alkyne 1,3-dipolar cycloaddition reaction in nucleoside, nucleotide, and oligonucleotide chemistry. Chemical Reviews, 109, 4207–4220.

11.

Huang

, Armstrong

E.A.

, Benavente

, Chinnaiyan

, Harari

P.M.

(2004) Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Research, 64, 5355–5362.

12.

Gridelli

, Bareschino

M.A.

, Schettino

, Rossi

, Maione

, Ciardiello

(2007) Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist, 12, 840–849.

13.

N.T.G.

, Nguyen

T.N.

, Dang

T.T.A.

, Hoang

T.P.

, Nguyen

T.A.

, Nguyen

H.T.

, Vu

Q.T.

, Nguyen

V.T.

(2017) Synthesis of several of 6-(prop-2-yn-1-yloxy)quinazolin-4-amine derivatives. Vietnam Journal of Chemistry, 55(5E34), 256–259.

14.

N.T.G.

, Dang

T.T.A.

, Hoang

T.P.

, Dinh

T.V.

, Nguyen

V.T.

(2016) Improved procedure for the synthesis of erlotinib. Vietnam Journal of Chemistry, 54(6E2), 1–5.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.79 MB

Design,Synthesis and Cytotoxic Evaluation of 4-Anilinoquinazoline– triazole–AZT Hybrids as Anticancer Agents

Abstract

Keywords

References

Supplementary Material